Trial · NCT01321879

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2019-12-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients. Trials, record NCT01321879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01321879

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
NCT number: NCT01321879
Status: Completed
Phases: Phase 2
Enrollment: 40 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Infection, Bacteremia
Interventions: Telavancin
First posted: 2011-03-24
Last updated: 2019-12-27
Results first posted: 2019-12-27

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Patient Clinical Response to Telavancin	From baseline up to 6 weeks, assessed every 7 days	Clinical response assessed: Cure (No fever/chills or symptoms + eradication causing organism); Improvement (Resolution local/systemic symptoms + no new systemic antibacterial treatment); Failure (IF one or more following: Persistence 1+ symptoms \[fever/chills\] + new systemic anti gram positive treatment, \> 72 hours after initiation study drug; or Relapse within 1 month completing antibiotic therapy; or Development of deep-seated infection not previously assessed); Indeterminate (clinical signs and symptoms cannot be assessed).

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Patient Clinical Response to Telavancin	From baseline up to 6 weeks, assessed every 7 days	Three patients received \<72 hours of Telavancin treatment and therefore were excluded from the efficacy analysis.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Patient Clinical Response to Telavancin	Telavancin		32		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Telavancin	39
Overall Study	COMPLETED	Telavancin	25
Overall Study	NOT COMPLETED	Telavancin	14

Source ClinicalTrials.gov

Adverse events96

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	General disorders	Telavancin	2	39	2
other	Acute coronary syndrome	Cardiac disorders	Telavancin	1	39	1
other	Acute kidney injury	Renal and urinary disorders	Telavancin	2	39	2
other	Alanine aminotransferase increased	Metabolism and nutrition disorders	Telavancin	1	39	1
other	Alkaline phosphatase increased	Metabolism and nutrition disorders	Telavancin	1	39	1
other	Anemia	Blood and lymphatic system disorders	Telavancin	10	39	13
other	Anorexia	Gastrointestinal disorders	Telavancin	2	39	2
other	Aspartate aminotransferase increased	Metabolism and nutrition disorders	Telavancin	1	39	1
other	Blood and lymphatic system disorders - (Other)	Blood and lymphatic system disorders	Telavancin	2	39	2
other	Blood bilirubin increased	Investigations	Telavancin	2	39	2

1 to 10 of 96Source ClinicalTrials.gov

See all 96 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Telavancin	7	39
Total, other adverse events	Telavancin	31	39
Total, serious adverse events	Telavancin	15	39

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
26482312	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01321879

GET https://conductscience.org/api/trials/v1/NCT01321879/events?page=2

API reference For AI assistants